Cardio Diagnostics Holdings (CDIO) Non-Current Assets (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Non-Current Assets of $1.8 million for Q1 2026, down 1.68% sequentially from $1.8 million in Q4 2025, and up 3.9% YoY from $1.7 million in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Non-Current Assets (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Non-Current Assets for 6 years, with the latest figure at $1.8 million in Q1 2026.
- Quarterly Non-Current Assets rose 3.9% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 0.94% YoY) and the FY2025 annual result came in at $1.8 million, up 1.16% from the prior year.
- Non-Current Assets slipped to $1.8 million in Q1 2026 per CDIO's latest filing, from $1.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $65.6 million in Q3 2022 and troughed at $363591.0 in Q4 2022.
- A 5-year average of $12.7 million and a median of $1.8 million in 2026 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 366.65% in 2023, down 99.36% in 2023.
- Over 5 years, Non-Current Assets stood at $363591.0 in 2022, then jumped by 366.65% to $1.7 million in 2023, then gained by 7.53% to $1.8 million in 2024, then advanced by 1.16% to $1.8 million in 2025, then slipped by 1.68% to $1.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1.8 million, $1.8 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.77 Mn |
| Mar 31, 2026 | 1.81 Mn |
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.75 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Jun 30, 2024 | 1.86 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 502,186.00 |
| Mar 31, 2023 | 413,580.00 |
| Dec 31, 2022 | 363,591.00 |
| Sep 30, 2022 | 65.57 Mn |
| Jun 30, 2022 | 65.01 Mn |
| Mar 31, 2022 | 65.00 Mn |
| Dec 31, 2021 | 298,487.00 |